Data from O'Neil et al., differ from the current study in that they assessed the impact of acute SGLT 1 and 2 inhibition (phlorizin); not specific SGLT‐2 inhibition, in a similar model of diabetes. Here, SLC5A2 is linked to diabetes mellitus.